Abstract: SA-PO665
The Factors for Maintenance of B Cell Depletion After Use of Rituximab in Renal Disorders
Session Information
- Glomerular Diseases: ANCA, Anti-GBM, Kidney Biopsy
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Yu, Binfeng, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
- Han, Fei, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Background
The duration of B-cell depletion(BCD) after rituximab administration may be related to the disease recurrence. We aimed to explore the factors which may influence the duration of BCD(CD19 positive B cell count<5/μL) after the use of rituximab in patients with kidney diseases.
Methods
Patients received rituximab for renal causes and were regularly monitored every 2-3 months on B cell counts were enrolled. Prognostic factors for maintenance of BCD were identified through Cox proportional hazards model where the optimal cutoff values were determined using an online statistical tool Cutoff Finder.
Results
There were 47 patients who received a median of 900mg (range,300-1500mg) of rituximab with 100% achieving BCD and 49% experiencing B cell reconstitution during follow-up. The optimal cutoff value of dose to body-surface-area ratio (DBR) was 529.5mg/m2 in total and that of circulating T helper (Th) cell count was 978.5/μL. In multivariate analyses, high DBR(>529.5mg/m2) was identified as an independent protective factor (HR0.42,p=0.024) and high circulating Th cell count (>978.5/μL) was identified as an independent risk factor (HR2.98,p=0.037) for maintenance of BCD. High Th cell count (>978.5/μL) was also associated with manifestation of nephrotic syndrome, increased CD19 positive B cell counts and T killer cell counts.
Conclusion
DBR and Th cell counts were of predictive values for maintenance of BCD after use of rituximab in patients with renal disorders.
Prognostic parameters for maintenance of B cell depletion (BCD) via Cox proportional hazards model
Funding
- Government Support - Non-U.S.